Jan 2, 2026

A Big Ten CRC study, BTCRC-GI21-500, will be presented as a Trials in Progress poster at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 in San Francisco. This study is led by Ashish Manne, MBBS, of The Ohio State University.

  • Session Details: Poster Session B, on January 9, 11:30 am – 1:00 pm
  • Presentation Title: A phase II trial of perioperative tumor treating fields (NovoTTF-200T[P]) combined with gemcitabine and nab-paclitaxel in resectable pancreatic adenocarcinoma: Big Ten Cancer Research Consortium (BTCRC-GI21-500)
  • Abstract: TPS797
  • Poster Board: N7

This is a multicenter, single-arm phase II study evaluating the perioperative use of tumor treating fields (TTFields) in combination with gemcitabine and nab-paclitaxel in patients with resectable pancreatic ductal adenocarcinoma. TTFields exert anti-mitotic effects by disrupting microtubule assembly and cytokinesis through alternating electric fields, and prior preclinical and clinical data suggest additive activity when combined with chemotherapy.

The study uses a Bayesian Optimal Phase II (BOP2) design with dual primary endpoints of 2-year overall survival and resection rate. Secondary objectives include safety and tolerability, overall response rate, TTFields compliance, chemotherapy dose intensity, and long-term survival outcomes. The trial plans to enroll up to 38 patients and is currently open to accrual across participating Big Ten CRC member institutions.

See abstract: https://www.asco.org/abstracts-presentations/256090

Learn more: https://bigtencrc.org/clinical-research/current-trials/btcrc-gi21-500/

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups. 

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional, and undergraduate teaching, and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness, and competitiveness. The broad-based programs of the 18 Big Ten institutions provide direct financial support for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women. For more information, visit www.bigten.org.